

Implementing MOA-Reflective ADCC assays using Ready-to-Use KILR[®] Target & Effector Cells from Screening to Lot Release

Gaurav Agrawal, Ph.D. Scientific Development Manager

OUR EXPERTISE IN YOUR HANDS. DISCOVER CONFIDENTLY.

Visit us at booth: 326

Eurofins DiscoverX is a Global Leader in Cell-Based Assays for Screening, Profiling, Potency, & Lot Release Programs



The Eurofins Discovery PRODUCTS COMPANY

From Discovery to Development to Clinic to Post-Market

20+ Years of Enabling Drug Discovery and Development Programs


Image: constraint of the systemImage: constraint of		10+ Druggable target classes			20+ Core pate			cations across multiple
			55+ Qualified & MOA- based Bioassays	Validated >30 Billion Data P screened in assay service same assays				3 Certified CRO Partners Scientific training to enable global CROs
ICH Based Bioassay Qualification Facilitate downstream validation studies	Dedicated Scientific Experienced to scientific supp	eam providing	20+ Successful Assay Transfers At clients/affiliated CRO sites		fers RO sites	For pote testing	ency,	bal Programs stability and NAb

Largest Menu of Cell-Based Assays for Discovery, Potency, & NAb Assay Development



The Eurofins Discovery PRODUCTS COMPANY

>800 Cell lines to support bioassay development for major drug target classes



Cell-Mediated Cytotoxicity – A Rapidly Developing Area For Cancer Therapeutics


Therapeutic mAbs are the fastest growing class of biological therapeutics and more than100 mAbs are already approved by the FDA

Many of these therapeutic antibodies work by activating antibody-dependent cell-mediated cytotoxicity (ADCC) or through similar effector functions (ADCP, CDC, T-cell Redirection)

Starting from Phase I and even earlier, ADCC assays should be performed for assessment of therapeutic antibody potency and in other cases for safety

Effector	20
Cell	Cancer
CD16	cell

Therapeutic antibodies to induce ADCC approved in the US					
Antibody	Туре	Target			
Rituximab/other similar anti-CD20	Chimeric IgG1	CD20			
Trastuzumab	Humanized IgG1	HER2			
Alemtuzumab	Humanized IgG1	CD52			
Cetuximab	Chimeric IgG1	EGFR			
Ofatumumab	Human IgG1	CD20			
Pertuzumab	Humanized IgG1	HER2			
Dinutuximab	Chimeric IgG1	GD2			



FDA approves 100th monoclonal

DiscoverX

eurofins



Challenges with Existing Cytotoxicity Assays

🛟 eurofins

DiscoverX


The Eurofins Discovery PRODUCTS COMPANY

Radioactivity or fluorescent **KILR** - KILR[®] assays are **Dye-based** dye-based are inherently Little to no non-radioactive and Lum leaky – produce less robust background What are not leaky and high background scientists High assay background face.... [Antibody] Ease of - KILR cytotoxicity Low assay throughput implementation assays are highrestricts screening and from screening to throughput compatible characterization efficiency lot release (384-well) Surrogate assays fail - KILR assays are Physiologicallyto reflect the MOA end-point assays and reflective of "Predictive" and not specifically measures TRUE MOA "Reflective" target cell killing ADCC High donor-to-donor - KILR CD16 Eliminate donor variability associated Effector Cells are variability with effector cells single donor-derived Log [Anti-CD20 Ab] (ng/mL

Enzyme Fragment Complementation (EFC) Technology

eurofins DiscoverX


The Eurofins Discovery PRODUCTS COMPANY



KILR Cytotoxicity Assay Overview ADCC Example

eurofins DiscoverX

The Eurofins Discovery PRODUCTS COMPANY




ADCC Demonstrated Using KILR[®] Assay with a Variety of Antibodies, Antigens, and Cell Types

🔅 eurofins

DiscoverX

The Eurofins Discovery PRODUCTS COMPANY



KILR[®] ADCC Assay is Compatible with Multiple Effector Cell

Types

#74 (V/V)

Pool

15.2


15.5

1.128

1.161

DiscoverX The Eurofins Discovery PRODUCTS COMPANY

eurofins



4.54


3.76

3.63

Eliminating Donor Variability in ADCC Assays KILR[®] CD16 Effector Cells


🔅 eurofins

The Eurofins Discovery PRODUCTS COMPANY




Single Donor-Derived Engineered Effector Cells for ADCC

KILR[®] CD16 (V158) Effector Cells




- Primary human cytotoxic T lymphocytes (CTLs)
- Engineered to stably express CD16 (V158)
- Uniformly manufactured to ensure lot-to-lot consistency
- Low background, high killing capacity for implementing ADCC for lot release or characterization




Larger Assay Window Improves Analysis of Antibody Activity **eurofins ADCC** Assays


DiscoverX The Eurofins Discovery PRODUCTS COMPANY

Consistent pharmacology with lower effector:target ratios



KILR ARH-7	7 Cell Line	






Sample	EC ₅₀ , ng/mL	S/B	Max Cytotoxicity, %
KILR CD16 cells (12.5:1)	20.6	41.6	37%
PBMCs (25:1)	10.6	2.6	8.8%

MOA's Supported by KILR[®] Cytotoxicity Assays



The Eurofins Discovery PRODUCTS COMPANY


ADCC	ADCP	CDC	TCR	CAR-T
Antibody-Dependent Cellular Cytotoxicity	Antibody-Dependent Cellular Phagocytosis	Complement Dependent Cytotoxicity	T-cell Redirection (with Bi-Specific Ab)	Chimeric antigen receptor (on) T-cells
Effector cells engage with the target cells through the antibody and kill	Fc-dependent phagocytosis and lysosomal degradation	Activated complement system leads to formation of membrane attack complex (MAC)	Bi-specific antibody engages T-cell with cancer cells for killing	Engineered T-cells recognize and kill cancer cells
Effector Cell Granzyme and perforin (CD16) FCyRIIIa Target Antigen V Cytotoxicity KILR Target Cell	Macrophage Macrophage	Complement C1q Target Antigen	Activated T-Cell CD3 BITE CD19 CD19 CD19 CD19 CD19 CD19 CD19	Activated T-Cell CAR Target Antigen KILR Target Cell
				💣 KILR Reporter Protein




Easy-to-Use Assay Protocol KILR[®] Raji ADCC Bioassay Kit



DiscoverX



Bioassay Kit Includes Required Reagents for the Assay




Drug Discovery & Development Phase-Appropriate Solutions | Our Expertise in Your Hands – Discover Confidently

*Effector cells sold separately 15

Continuous Culture vs Ready-to-Assay Cell Formats KILR® Raji ADCC Bioassay Kit Performance




The Eurofins Discovery PRODUCTS COMPANY



Suitable for Screening and Rank Ordering of Antibodies KILR[®] Raji ADCC Bioassay Kit

Construction Const




Sample	Description	S/B	HillSlope	E _{Max}	EC ₅₀ , pg/mL
hCD20-mab13	Non-fucosylated anti-CD20 (Rituximab)	5.4	1.152	88%	92.8
hCD20-ga-mab13	Non-fucosylated anti-CD20 (Obinituzimab)	5.2	1.307	84%	46.5
hCD20-mab12	Fc Null variant of Rituximab				
hCD20-mab1	Wild-type Rituximab	4.5	1.270	69%	288
Isotype (IgG1)	Human IgG1 isotype control				

KILR Raji Bioassay identifies subtle differences to differentiate to obtain potency rank order

Repeatability (Over 3 Days); Single Analyst KILR[®] Raji ADCC Bioassay Kit

eurofins


The Eurofins Discovery PRODUCTS COMPANY



Parameter	Day 1	1 Day 2 Day 3		% RSD
EC ₅₀ , pg/mL	6.2	7.03	7.4	8.9%
S/B	9.8	10.6	8.3	12.2%
E _{Max} , %	135%	114%	75.8%	27.7%

Excellent inter-day reproducibility

Independent experiments performed on different days with same Bioassay cells from same lot



Analyst 2

eurofins

DiscoverX

The Eurofins Discovery PRODUCTS COMPANY

Consistent assay performance between individual analysts

Global Programs using DiscoverX Bioassays for Potency, Stability, & NAb Testing for Drug Release



DiscoverX

The Eurofins Discovery PRODUCTS COMPANY

SIRPα Bioassay	PD-1 Bioassay	VEGF Bioassay	Insulin Bioassay	CNR1 Bioassay	GLP1R Bioassay	IGF1R Bioassay	Bradykinin Bioassay	PTHR1 Bioassay
Multiple Programs in NA for originator biologics	Multiple Programs in NA and APAC	Multiple Programs in NA, EU and APAC	Multiple Programs in and APAC for clinical Development of	US based Biopharma for	Multiple Programs in NA, EU and APAC	Multiple Programs in NA and APAC for	US based CRO for undisclosed client	Multiple Programs in NA, EU and APAC
NAb assessment Programs at CROs	Clinical Development of Biosimilars	Clinical Development of Biosimilars	Biosimilars	originator biologic	Clinical Development of Biosimilars in NA	originator biologic		Clinical Development of Biosimilars
ErbB2/ErbB3 Bioassay	FGFR Bioassay	IL-1 Bioassay			**************************************	Melanocortin Bioassay	IL-2 Bioassay	IL-23 Assay
Multiple Programs in NA, EU and APAC Clinical Development of Biosimilars	NAb assessment program for US based Biopharma	Multiple Programs in NA for originator biologic		A STATE		European Biopharma for an originator biologic	Multiple Programs in NA and EU for originator biologic	US Based Biopharma for originator biologic
IL-10 Bioassay	GM-CSF Bioassay	IL-31 Bioassay				RANK Assay	MC4R Bioassay	CXCR2 Bioassay
Multiple Programs in NA for originator biologic	Multiple Programs in EU and NA for originator biologic	US based pharma for NAb assessment and potency testing Programs for originator biologic			*** }	Multiple Programs in and APAC for clinical Development of Biosimilars	Bioassay Program in EU for originator biologic	Bioassay Program in NA clinical development and drug release
AXL Bioassay	CSF2R Bioassay	CSF1R Bioassay	CXCR4 Bioassay	IL7R/CRLF2 Bioassay	CALCRL/RAMP3 Bioassay	KILR CD16 Effectors	FSHR Bioassay	IL7R/IL2R Bioassay
Bioassay Program in NA for originator biologic	Multiple Programs in NA and EU Clinical development and drug release	Multiple Programs in NA and EU Clinical development and release	NAb assessment program for EU based Biopharma	Drug Release Program in EU for originator biologic	Bioassay Program in NA clinical development and drug release	Multiple Programs in NA and EU for Cytotoxicity Release assay	Bioassay Program in APAC for Biosimilar	Bioassay Program in EU for originator biologic


Drug Discovery & Development Phase-Appropriate Solutions | Our Expertise in Your Hands – Discover Confident Key: NA = North America; EU = Europe; APAC = Asia Pacific; NAb = Neutralizing Antibody 20

Construction Const



Your Target Biology, Our Expertise — Building a Better Assay Together

- Development Expertise Decades of cell-based assay development, cell line engineering, and recombinant enzyme development expertise
- Cell Line Engineering Capability Exogenous expression approaches (constitutive vs inducible) or gene editing (e.g. KO/KI with CRISPR/Cas9)
- Collaborative Consultative assay development with regular updates through a dedicated project manager
- Complete Solution Customized assay development with screening and profiling services within the same team




CAD Services Capabilities

Multiple Key Capabilities, One Service Provider Eurofins Discovery Biotherapeutics Services

🔅 eurofins

DiscoverX

The Eurofins Discovery PRODUCTS COMPANY



Summary & Conclusions



The Eurofins Discovery PRODUCTS COMPANY

DiscoverX offers the industry's largest menu of cellbased assays with over 1500 off-the-shelf products


KILR[®] cytotoxicity platform offers MOA-based assays for variety of cell-mediated cytotoxicity applications such as:

ADCC, ADCP, CDC, T-cell Redirection and CAR-T

KILR CD16 Effector Cells offer a unique solution solving donor variability issue when sourcing effector cells

KILR Raji Bioassay allows discrimination of differences in Fab and Fc regions to enable rank ordering of antibodies






Pre-order your KILR Raji

Special Promotion

ADCC Bioassay Kits by June 30th & receive a 22% discount!



Visit discoverx.com/KILRbioassays to learn more